,0
zip,46285
sector,Healthcare
fullTimeEmployees,35000
longBusinessSummary,"Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana."
city,Indianapolis
phone,317 276 2000
state,IN
country,United States
companyOfficers,[]
website,https://www.lilly.com
maxAge,1
address1,Lilly Corporate Center
industry,Drug Manufacturersâ€”General
ebitdaMargins,0.34342
profitMargins,0.19709998
grossMargins,0.75376
operatingCashflow,7260700160
revenueGrowth,0.075
operatingMargins,0.28877002
ebitda,9725100032
targetLowPrice,304.28
recommendationKey,buy
grossProfits,21345300000
freeCashflow,5142062592
targetMedianPrice,304.28
currentPrice,289.02
earningsGrowth,-0.183
currentRatio,1.226
returnOnAssets,0.1071
numberOfAnalystOpinions,1
targetMeanPrice,304.28
debtToEquity,192.382
returnOnEquity,0.74522
targetHighPrice,304.28
totalCash,3913400064
totalDebt,17612199936
totalRevenue,28318400512
totalCashPerShare,4.337
financialCurrency,USD
revenuePerShare,31.223
quickRatio,0.799
recommendationMean,2
exchange,NYQ
shortName,Eli Lilly and Company
longName,Eli Lilly and Company
exchangeTimezoneName,America/New_York
exchangeTimezoneShortName,EDT
isEsgPopulated,False
gmtOffSetMilliseconds,-14400000
quoteType,EQUITY
symbol,LLY
messageBoardId,finmb_285467
market,us_market
annualHoldingsTurnover,
enterpriseToRevenue,9.699
beta3Year,
enterpriseToEbitda,28.243
52WeekChange,0.55103576
morningStarRiskRating,
forwardEps,8.95
revenueQuarterlyGrowth,
sharesOutstanding,952347008
fundInceptionDate,
annualReportExpenseRatio,
totalAssets,
bookValue,9.937
sharesShort,6593440
sharesPercentSharesOut,0.0069
fundFamily,
lastFiscalYearEnd,1640908800
heldPercentInstitutions,0.84158
netIncomeToCommon,5581700096
trailingEps,6.12
lastDividendValue,0.98
SandP52WeekChange,0.14403355
priceToBook,29.085236
heldPercentInsiders,0.00156
nextFiscalYearEnd,1703980800
yield,
mostRecentQuarter,1640908800
shortRatio,2.26
sharesShortPreviousMonthDate,1644883200
floatShares,900479267
beta,0.408464
enterpriseValue,274670764032
priceHint,2
threeYearAverageReturn,
lastSplitDate,876960000
lastSplitFactor,2:1
legalType,
lastDividendDate,1644796800
morningStarOverallRating,
earningsQuarterlyGrowth,-0.185
priceToSalesTrailing12Months,9.719734
dateShortInterest,1647302400
pegRatio,5.74
ytdReturn,
forwardPE,32.292736
lastCapGain,
shortPercentOfFloat,0.0083
sharesShortPriorMonth,5362806
impliedSharesOutstanding,0
category,
fiveYearAverageReturn,
previousClose,287.69
regularMarketOpen,288.5
twoHundredDayAverage,249.83325
trailingAnnualDividendYield,0.011818277
payoutRatio,0.5556
volume24Hr,
regularMarketDayHigh,291.65
navPrice,
averageDailyVolume10Day,3333330
regularMarketPreviousClose,287.69
fiftyDayAverage,254.0706
trailingAnnualDividendRate,3.4
open,288.5
toCurrency,
averageVolume10days,3333330
expireDate,
algorithm,
dividendRate,3.92
exDividendDate,1644796800
circulatingSupply,
startDate,
regularMarketDayLow,287.5
currency,USD
trailingPE,47.22549
regularMarketVolume,2400056
lastMarket,
maxSupply,
openInterest,
marketCap,275247333376
volumeAllCurrencies,
strikePrice,
averageVolume,2848145
dayLow,287.5
ask,292.5
askSize,1000
volume,2400056
fiftyTwoWeekHigh,295.33
fromCurrency,
fiveYearAvgDividendYield,2.01
fiftyTwoWeekLow,178.58
bid,266.94
tradeable,False
dividendYield,0.0136
bidSize,1100
dayHigh,291.65
regularMarketPrice,289.02
preMarketPrice,
logo_url,https://logo.clearbit.com/lilly.com
